GLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25–$1,350/mo)

Verified April 17, 2026: GLP-1 medications — Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo — cost between $25 and $1,350 per month, verified across 48 telehealth providers. With a manufacturer savings card + commercial insurance: Wegovy and Zepbound copays drop to $25/month (max $1,300/year). Without insurance: Enhance MD at $115/mo for compounded semaglutide, Strut Health at $149/mo for oral semaglutide, Enhance MD at $149/mo for compounded tirzepatide, compounded semaglutide / $149/mo compounded tirzepatide, Foundayo (orforglipron) oral pill at $149/mo (2.4mg starter via LillyDirect), Eden Health at $249/mo for telehealth with brand + compounded options plus quarterly lab panels included, brand-name injectable via LillyDirect at $299–$449/mo (Zepbound) or NovoCare at $199/mo introductory / $349/mo ongoing (Wegovy). Medicare Part D beneficiaries get $50/month via the GLP-1 Bridge program starting July 1, 2026.

Quick answer by scenario: Have commercial insurance that covers Wegovy/Zepbound/Foundayo → apply the savings card, pay $25/mo. Uninsured and want cheapest cash-pay → Enhance MD ($115) or Strut Health ($149 oral). Uninsured and want a brand-name pill → Foundayo at $149/mo (lowest dose) via LillyDirect. Uninsured and want brand-name injectable → LillyDirect ($299/mo Zepbound) or NovoCare ($199/mo intro Wegovy). Uninsured and want comprehensive clinical oversight → Eden Health $249/mo includes quarterly lab panels and board-certified obesity medicine physicians. Medicare beneficiary → the GLP-1 Bridge program starts July 1 at $50/mo. Use our cost calculator to estimate your monthly spend, see all providers sorted by lowest price, or take the 60-second match quiz.

This guide breaks down every pricing option: brand-name list prices, manufacturer direct-to-consumer programs (LillyDirect, NovoCare), the new Foundayo oral pill, compounded telehealth providers, savings cards, Medicare/Medicaid coverage, and how the savings structures actually work. All prices verified April 17, 2026 against provider websites and manufacturer announcements. Sources: CMS GLP-1 Bridge Demonstration, Zepbound savings card terms, Wegovy savings offer, Foundayo savings card.

How Much Do GLP-1 Medications Cost Without Insurance?

List prices (what pharmacies charge before discounts) don't reflect what most people pay. Here's the full picture:

How Do GLP-1 Savings Cards Work?

Both major manufacturers offer significant savings cards. These are the most impactful way to reduce your cost if you have commercial insurance:

Novo Nordisk (Wegovy, Ozempic, Saxenda): If you have commercial insurance that covers your medication, savings cards can bring your copay down to $25 per fill. For uninsured patients, Novo Nordisk offers a $199/month introductory price for Wegovy and Ozempic injectables for the first two months, then $349/month ongoing (through June 30, 2026). Novo also launched a Wegovy subscription program at $249–$329/month (injection) or $249–$289/month (oral pill) through partners like Ro, WeightWatchers, and LifeMD. Text SAVE to 83757 for a digital savings card.

Eli Lilly (Zepbound, Mounjaro, Foundayo): With commercial insurance coverage, savings cards offer copays as low as $25 per fill (max $1,300/year). If your insurance doesn't cover Zepbound, the savings card price is $499/month. LillyDirect sells self-pay Zepbound KwikPens at $299–$449/month depending on dose (through December 31, 2026). Foundayo (orforglipron), FDA-approved April 1, 2026, is available via LillyDirect at $149–$449/month self-pay or $25/month with a commercial insurance savings card. All Lilly savings cards expire December 31, 2026.

Does Medicare Cover GLP-1 Medications?

This is the biggest cost development of 2026. CMS announced the Medicare GLP-1 Bridge Demonstration, launching July 2026:

• •Beneficiary copay: $50/month for GLP-1 medications
• •Negotiated manufacturer price: $245/month (paid by the program)
• •Covers Wegovy, Zepbound (KwikPen only), and Foundayo
• •Eligibility: Medicare Part D enrollees meeting BMI criteria and related health conditions
• •Estimated ~10% of Medicare beneficiaries expected to qualify

The longer-term BALANCE Model is set to launch in January 2027 for Medicare and May 2026 for state Medicaid agencies that opt in. This combines GLP-1 access with lifestyle supports and allows CMS to negotiate drug pricing on behalf of participating plans.

Does Insurance Cover GLP-1 Medications for Weight Loss?

Insurance coverage for GLP-1s is actually getting more restrictive for weight loss in 2026, despite growing demand:

• •8.5% of commercially insured people (16+ million) have no GLP-1 coverage for weight loss at all
• •The number of people without Wegovy coverage specifically increased 42% vs 2025 — over 41 million without access
• •Major insurers including BCBS, Cigna, and UnitedHealthcare implemented new restrictions as of January 2026, mostly limiting coverage to Type 2 diabetes only
• •Most insurers still cover Ozempic/Mounjaro for diabetes — restrictions primarily hit weight-loss-only indications

How Much Do Telehealth GLP-1 Programs Cost?

Online telehealth providers often offer lower total costs by bundling consultation fees with medication. Here's a sample of what platforms charge:

We rank 48 telehealth GLP-1 providers by price — see the full list sorted cheapest-first, or take the 60-second match quiz to find the best provider for your insurance, budget, and medication preference. For tirzepatide specifically, see our cheapest tirzepatide page.

Can You Use FSA or HSA for GLP-1 Medications?

GLP-1 medications are FSA and HSA eligible when prescribed for a documented medical condition (obesity, Type 2 diabetes, metabolic syndrome). This applies to all brand-name GLP-1s, compounded versions with a valid prescription, and in many cases the telehealth consultation fees as well. You'll need a valid prescription and medical documentation — purely cosmetic weight loss without a medical diagnosis may not qualify.

Does Medicaid Cover GLP-1 Medications?

As of January 2026, only 13 state Medicaid fee-for-service programs cover GLP-1s for obesity treatment — down from 16. California, New Hampshire, Pennsylvania, and South Carolina recently eliminated coverage. Michigan added strict requirements including morbid obesity classification and documented failure of other interventions.

The BALANCE Model allows state Medicaid agencies to opt in starting May 2026, with CMS negotiating drug pricing on their behalf. This could expand access, but it's voluntary.